1 results match your criteria: "National and Kapodistrian University of Athens (Spyridon Pantzios[Affiliation]"
Efficacy of atezolizumab-bevacizumab combination therapy early after recurrence of hepatocellular carcinoma following resection or ablation with a curative intent.
Ann Gastroenterol
October 2024
Academic Department of Internal Medicine - Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens (Spyridon Pantzios, Antonia Syriha, Ioanna Stathopoulou, Sofia Rellou, Georgia Barla, Ioannis Elefsiniotis).
Background: The pattern of hepatocellular carcinoma (HCC) recurrence after resection/ablation is intrahepatic and/or systemic. The efficacy of atezolizumab-bevacizumab treatment as early therapy after recurrence has not been extensively evaluated.
Methods: We evaluated 32 patients (group A) with early HCC recurrence after resection/ablation and 24 patients (group B) initially diagnosed as Barcelona Clinic Liver Cancer (BCLC)-C, all treated with atezolizumab-bevacizumab.